Search Results

You are looking at 1 - 10 of 105 items for :

  • medullary thyroid cancer x
Clear All
Free access

M. Schlumberger, L. Bastholt, H. Dralle, B. Jarzab, F. Pacini, and J.W.A. Smit

Methods of Development of Evidence-Based Guidelines The European Thyroid Association (ETA) Executive Committee launched a taskforce to produce guidelines on the treatment of metastatic medullary thyroid cancer (MTC). A chairperson was selected

Open access

Camille Buffet, Sophie Leboulleux, Françoise Kraeber-Bodéré, Caroline Bodet-Milin, Laure Cabanes, Anthony Dohan, Pascal Leprince, Martin Schlumberger, Olivier Huillard, and Lionel Groussin

from medullary thyroid cancers (MTC) are uncommon. Their frequency in large autopsy series in patients with thyroid cancers is low, between 0 and 5% [ 1 - 5 ]. Given the rarity of this metastatic location, the outcome remains unclear. The average length

Free access

R. Elisei, M. Alevizaki, B. Conte-Devolx, K. Frank-Raue, V. Leite, and G.R. Williams

Introduction Several guidelines have already been published on the diagnosis, management, and treatment of medullary thyroid cancer (MTC) [ 1 , 2 , 3 , 4 ], but there are no guidelines devoted specifically to RET genetic screening in

Free access

Laura Moss, Catrin Cox, Jonathan Wadsley, Kate Newbold, Mark W.J. Strachan, Maralyn Druce, Neil Tolley, Kathryn Graham, Sarah Jefferies, Lydia Fresco, Suganya Sivabalasingham, Alistair Balfour, and Chris Hurt

Introduction Medullary thyroid cancer (MTC) is a rare variant of thyroid cancer with different aetiology, presentation, treatment and symptoms compared to the more common differentiated thyroid cancers (DTC). Based on Cancer Research UK (CRUK

Open access

Simona Censi, Jacopo Manso, Teresa Benvenuti, Ilaria Piva, Maurizio Iacobone, Alberto Mondin, Francesca Torresan, Daniela Basso, Gino Crivellari, Stefania Zovato, and Caterina Mian

Introduction Medullary thyroid cancer (MTC) originates from parafollicular C-cells and represents 2% of all thyroid malignancies and 0.4–1.4% of all thyroid nodules ( 1 ). MTC is sporadic in 75–80% of cases or manifests as a hereditary tumor

Free access

Lars Bastholt, Michael C. Kreissl, Dagmar Führer, Ana L. Maia, Laura D. Locati, Léa Maciel, Yi Wu, Kevin N. Heller, Alan Webster, and Rossella Elisei

Introduction Medullary thyroid cancer (MTC) is a malignancy of the parafollicular C cells of the thyroid gland, and it accounts for an estimated 4% of thyroid cancers [ 1 , 2 ]. MTC can only be cured by surgery and, until recently, the

Open access

Luciana Puleo, Laura Agate, Irene Bargellini, Giuseppe Boni, Paolo Piaggi, Claudio Traino, Tommaso Depalo, Giulia Lorenzoni, Francesca Bianchi, Duccio Volterrani, Sandra Brogioni, Valeria Bottici, Maurizia Rossana Brunetto, Barbara Coco, Eleonora Molinaro, and Rossella Elisei

Introduction Medullary thyroid cancer (MTC) is a neuroendocrine tumor arising from parafollicular or calcitonin-producing C cells that retain the biochemical and pathological features of the cells from which it derives. MTC accounts for 3

Free access

Cléber P. Camacho, Susan C. Lindsey, Teresa S. Kasamatsu, Alberto L. Machado, João Roberto M. Martins, Rosa Paula M. Biscolla, Magnus R. Dias da Silva, José Gilberto H. Vieira, and Rui M.B. Maciel

Introduction Serum calcitonin (sCT) is a useful biomarker for medullary thyroid cancer (MTC) and is employed for its diagnosis and follow-up monitoring [ 1 ]. In addition, some guidelines advocate sCT measurements for the differential

Open access

Ségolène Hescot, Julien Masliah-Planchon, Pauline du Rusquec, Célia Dupain, Maud Kamal, Vincent Servois, and Ivan Bieche

the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer . Critical Reviews in Clinical Laboratory Sciences 2016 53 217 – 227 . ( ) 26678667 10.3109/10408363.2015.1129529 8

Open access

Stéphane Bardet, Renaud Ciappuccini, Livia Lamartina, and Sophie Leboulleux

selpercatinib. Introduction Serum tumour markers are important tools in the management of patients with medullary thyroid carcinoma (MTC) ( 1 ). Serum calcitonin (CT) and carcinoembryonic antigen (CEA) are produced by neoplastic C-cells, and their